HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late, which are much ...

A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous ...

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads. With sales ...

Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 ...

As a result, many analysts are adopting a cautious stance on HIMS stock, waiting for clearer signs of stability before making ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.

The market overreacted to HIMS’ stock drop, in my view. 2025 revenue guidance of $2.29-$2.39 billion and a 3.6x multiple on its $8.3 billion market cap suggest undervaluation. HIMS’ PEG ratio ...

Hims & Hers is a newfangled telehealth company that started to ride the waves of GLP-1 weight loss medications. As waves go, this one’s given the stock a heck of ride; way up and then all the ...